Clinical Aspects of Regenerative Medicine

Immune System

Erszebet Szilagyi, Premenand Sundivakkam, Tamara Nunez, Kavitha Premenand, Norma S Kenyon, Amelia Bartholomew

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The immune system can powerfully mobilize inflammatory cells to combat invading organisms, such as bacteria or viruses, but can also orchestrate the right balance of inflammatory components required to initiate tissue repair and regeneration following injury. Inflammatory responses have a finite initiation and to prevent ongoing host tissue damage, a finite resolution. However, there are instances in which such inflammation continues unabated, such as the nonhealing wound, chronic rejection of a transplanted organ or tissue, or the ongoing tissue destruction observed in autoimmune diseases. Recapitulating the body's own method of ending the inflammatory process has been the foundation of a number of strategies involving the regeneration of the immune system. These strategies can be divided by their cell of origin, hematopoietic cells, which are progenitors of all the cells of the immune system or nonhematopoietic stromal-type cells, which intimately interface with hematopoietic cells and provide regulation of the immune system. In hematopoietic cell-based strategies, there are two broad categories: (1) redesigning the entire immune system through partial or full replacement (mixed or full chimerism, respectively) and (2) selective component therapy aimed at reducing specific deleterious immune effects. Nonhematopoietic-based or stromal cell therapies can address both immune responses and facilitate regenerative responses directly through the production of matrix, growth factors, and targeted recruitment of proregenerative cell types. The manner in which hematopoietic and nonhematopoietic cell strategies are undertaken, the sources of cells used, preclinical efficacy studies, clinical outcomes, if known, and potential obstacles are discussed.

Original languageEnglish (US)
Title of host publicationTranslational Regenerative Medicine
PublisherElsevier Inc.
Pages507-526
Number of pages20
ISBN (Print)9780124104570, 9780124103962
DOIs
StatePublished - Dec 2 2014

Fingerprint

Regenerative Medicine
Immune System
Stromal Cells
Regeneration
Chimerism
Wounds and Injuries
Cell- and Tissue-Based Therapy
Autoimmune Diseases
Intercellular Signaling Peptides and Proteins
Stem Cells
Outcome Assessment (Health Care)
Viruses
Inflammation
Bacteria

Keywords

  • Autoimmune
  • Chimerism
  • Clinical trials
  • Dendritic cells
  • Hematopoietic stem cells
  • Mesenchymal stem cells
  • Myeloid suppressor cells
  • Preclinical
  • Regulatory T cells
  • Tolerance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Szilagyi, E., Sundivakkam, P., Nunez, T., Premenand, K., Kenyon, N. S., & Bartholomew, A. (2014). Clinical Aspects of Regenerative Medicine: Immune System. In Translational Regenerative Medicine (pp. 507-526). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-410396-2.00037-2

Clinical Aspects of Regenerative Medicine : Immune System. / Szilagyi, Erszebet; Sundivakkam, Premenand; Nunez, Tamara; Premenand, Kavitha; Kenyon, Norma S; Bartholomew, Amelia.

Translational Regenerative Medicine. Elsevier Inc., 2014. p. 507-526.

Research output: Chapter in Book/Report/Conference proceedingChapter

Szilagyi, E, Sundivakkam, P, Nunez, T, Premenand, K, Kenyon, NS & Bartholomew, A 2014, Clinical Aspects of Regenerative Medicine: Immune System. in Translational Regenerative Medicine. Elsevier Inc., pp. 507-526. https://doi.org/10.1016/B978-0-12-410396-2.00037-2
Szilagyi E, Sundivakkam P, Nunez T, Premenand K, Kenyon NS, Bartholomew A. Clinical Aspects of Regenerative Medicine: Immune System. In Translational Regenerative Medicine. Elsevier Inc. 2014. p. 507-526 https://doi.org/10.1016/B978-0-12-410396-2.00037-2
Szilagyi, Erszebet ; Sundivakkam, Premenand ; Nunez, Tamara ; Premenand, Kavitha ; Kenyon, Norma S ; Bartholomew, Amelia. / Clinical Aspects of Regenerative Medicine : Immune System. Translational Regenerative Medicine. Elsevier Inc., 2014. pp. 507-526
@inbook{26a65b49fe68449f9abd42b164a14a81,
title = "Clinical Aspects of Regenerative Medicine: Immune System",
abstract = "The immune system can powerfully mobilize inflammatory cells to combat invading organisms, such as bacteria or viruses, but can also orchestrate the right balance of inflammatory components required to initiate tissue repair and regeneration following injury. Inflammatory responses have a finite initiation and to prevent ongoing host tissue damage, a finite resolution. However, there are instances in which such inflammation continues unabated, such as the nonhealing wound, chronic rejection of a transplanted organ or tissue, or the ongoing tissue destruction observed in autoimmune diseases. Recapitulating the body's own method of ending the inflammatory process has been the foundation of a number of strategies involving the regeneration of the immune system. These strategies can be divided by their cell of origin, hematopoietic cells, which are progenitors of all the cells of the immune system or nonhematopoietic stromal-type cells, which intimately interface with hematopoietic cells and provide regulation of the immune system. In hematopoietic cell-based strategies, there are two broad categories: (1) redesigning the entire immune system through partial or full replacement (mixed or full chimerism, respectively) and (2) selective component therapy aimed at reducing specific deleterious immune effects. Nonhematopoietic-based or stromal cell therapies can address both immune responses and facilitate regenerative responses directly through the production of matrix, growth factors, and targeted recruitment of proregenerative cell types. The manner in which hematopoietic and nonhematopoietic cell strategies are undertaken, the sources of cells used, preclinical efficacy studies, clinical outcomes, if known, and potential obstacles are discussed.",
keywords = "Autoimmune, Chimerism, Clinical trials, Dendritic cells, Hematopoietic stem cells, Mesenchymal stem cells, Myeloid suppressor cells, Preclinical, Regulatory T cells, Tolerance",
author = "Erszebet Szilagyi and Premenand Sundivakkam and Tamara Nunez and Kavitha Premenand and Kenyon, {Norma S} and Amelia Bartholomew",
year = "2014",
month = "12",
day = "2",
doi = "10.1016/B978-0-12-410396-2.00037-2",
language = "English (US)",
isbn = "9780124104570",
pages = "507--526",
booktitle = "Translational Regenerative Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Clinical Aspects of Regenerative Medicine

T2 - Immune System

AU - Szilagyi, Erszebet

AU - Sundivakkam, Premenand

AU - Nunez, Tamara

AU - Premenand, Kavitha

AU - Kenyon, Norma S

AU - Bartholomew, Amelia

PY - 2014/12/2

Y1 - 2014/12/2

N2 - The immune system can powerfully mobilize inflammatory cells to combat invading organisms, such as bacteria or viruses, but can also orchestrate the right balance of inflammatory components required to initiate tissue repair and regeneration following injury. Inflammatory responses have a finite initiation and to prevent ongoing host tissue damage, a finite resolution. However, there are instances in which such inflammation continues unabated, such as the nonhealing wound, chronic rejection of a transplanted organ or tissue, or the ongoing tissue destruction observed in autoimmune diseases. Recapitulating the body's own method of ending the inflammatory process has been the foundation of a number of strategies involving the regeneration of the immune system. These strategies can be divided by their cell of origin, hematopoietic cells, which are progenitors of all the cells of the immune system or nonhematopoietic stromal-type cells, which intimately interface with hematopoietic cells and provide regulation of the immune system. In hematopoietic cell-based strategies, there are two broad categories: (1) redesigning the entire immune system through partial or full replacement (mixed or full chimerism, respectively) and (2) selective component therapy aimed at reducing specific deleterious immune effects. Nonhematopoietic-based or stromal cell therapies can address both immune responses and facilitate regenerative responses directly through the production of matrix, growth factors, and targeted recruitment of proregenerative cell types. The manner in which hematopoietic and nonhematopoietic cell strategies are undertaken, the sources of cells used, preclinical efficacy studies, clinical outcomes, if known, and potential obstacles are discussed.

AB - The immune system can powerfully mobilize inflammatory cells to combat invading organisms, such as bacteria or viruses, but can also orchestrate the right balance of inflammatory components required to initiate tissue repair and regeneration following injury. Inflammatory responses have a finite initiation and to prevent ongoing host tissue damage, a finite resolution. However, there are instances in which such inflammation continues unabated, such as the nonhealing wound, chronic rejection of a transplanted organ or tissue, or the ongoing tissue destruction observed in autoimmune diseases. Recapitulating the body's own method of ending the inflammatory process has been the foundation of a number of strategies involving the regeneration of the immune system. These strategies can be divided by their cell of origin, hematopoietic cells, which are progenitors of all the cells of the immune system or nonhematopoietic stromal-type cells, which intimately interface with hematopoietic cells and provide regulation of the immune system. In hematopoietic cell-based strategies, there are two broad categories: (1) redesigning the entire immune system through partial or full replacement (mixed or full chimerism, respectively) and (2) selective component therapy aimed at reducing specific deleterious immune effects. Nonhematopoietic-based or stromal cell therapies can address both immune responses and facilitate regenerative responses directly through the production of matrix, growth factors, and targeted recruitment of proregenerative cell types. The manner in which hematopoietic and nonhematopoietic cell strategies are undertaken, the sources of cells used, preclinical efficacy studies, clinical outcomes, if known, and potential obstacles are discussed.

KW - Autoimmune

KW - Chimerism

KW - Clinical trials

KW - Dendritic cells

KW - Hematopoietic stem cells

KW - Mesenchymal stem cells

KW - Myeloid suppressor cells

KW - Preclinical

KW - Regulatory T cells

KW - Tolerance

UR - http://www.scopus.com/inward/record.url?scp=84942779134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942779134&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-410396-2.00037-2

DO - 10.1016/B978-0-12-410396-2.00037-2

M3 - Chapter

SN - 9780124104570

SN - 9780124103962

SP - 507

EP - 526

BT - Translational Regenerative Medicine

PB - Elsevier Inc.

ER -